ArticleFrontiers in aging2025
Possibility of screening for mild cognitive impairment via an eye tracking-based cognitive scale.
Article in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Montreal Cognitive Assessment (MoCA) is widely used as a screening test for mild cognitive impairment (MCI). However, the MoCA takes approximately 15 min to administer and evaluate by skilled examiners, such as medical professionals. This study assessed whether an eye tracking-based cognitive scale using virtual reality (VR) was accurate and efficient to screen for MCI. Methods: This study included 143 patients. The Virtual Reality-Based Cognitive Function Examination (VR-E) was used with all participants to evaluate their memory, judgment, spatial cognition, calculation, and language function. Results: Significant differences were observed in all cognitive domains of memory, judgment, spatial cognition, calculation, and language function between the Alzheimer's disease (AD), MCI, and older healthy control (HC) groups. The area under the curve value of the VR-E score for the HC and MCI groups was 0.857, and that for the AD and MCI groups was 0.870. The correlation coefficient between the MMSE and VR-E scores was 0.566 (p < 0.001), and that between the Japanese version of the MoCA (MoCA-J) and VR-E scores was 0.648 (p < 0.001), which indicated a moderate correlation in both comparisons. Conclusion: The VR-E had the same diagnostic performance results as the MoCA-J, thus the VR-E has potential for use in screening patients for MCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.